查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2020214

抗精神病藥物市場規模、佔有率、成長及全球產業分析：按類型、應用和地區分類，並預測至2026-2034年

Antipsychotic Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 195 Pages | 商品交期: 請詢問到貨日

價格

抗精神病藥物市場的成長要素

全球抗精神病藥物市場預計在2025年達到185.1億美元，2026年成長至197.1億美元，最終在2034年達到274.8億美元，預測期內複合年成長率（CAGR）為5.24%。北美地區預計將在2025年佔全球市場的主導地位，市場佔有率高達52.32%，這主要得益於該地區精神疾病的高發生率、眾多主要企業生物製藥公司的強大影響力以及對技術先進的抗精神病藥物的廣泛應用。

市場概覽

思覺失調症、躁鬱症和憂鬱症等精神疾病是抗精神病藥物市場的主要促進因素。精神病是這些疾病的主要症狀，會影響患者對現實的感知和訊息處理能力。思覺失調症和雙相情感障礙盛行率的上升推動了全球對有效抗精神病藥物的需求。此外，新型劑型的引入，特別是長效注射劑（LAI），顯著提高了治療順從性和療效。

此外，新冠疫情加速了精神科護理領域遠距遠端醫療的普及，並提高了藥物的使用率，從而對市場產生了積極影響。隨著醫療保健系統的改善和治療可近性的提高，預計2024年至2032年間市場成長將趨於穩定。

市場區隔

疾病特異性：

  • 思覺失調症：由於其在全球範圍內的高發病率以及幾款創新產品的推出，這是成長最快的細分市場。
  • 雙極性情感障礙：這是第二大類精神疾病，目前已有藥物可以幫助穩定症狀。終生盛行率約1%，一年盛行率為0.5%。
  • 單相憂鬱症：這是第三大類，Rexulti 等藥物可以緩解症狀。
  • 失智症：由於美國食品藥物管理局 (FDA) 的黑框警告限制了抗精神病藥物在老年患者中的使用，因此這部分人群佔比很小。

依藥物類型：

  • 除了安全性更高之外，第二代抗精神病藥物，包括Seroquel緩釋片、Zyprexa平、維瑞樂、英維加哈菲拉和雷舒利等藥物，預計到 2026 年將主導市場，佔 76.12% 的市場佔有率。
  • 第三代產品預計將展現出最高的複合年成長率，這得益於新產品的推出和技術的進步。
  • 第一代產品由於神經系統副作用風險較高，生長速度最慢。

按藥物分類：

  • Aripiprazole正透過向第三代藥物的過渡和關鍵產品核可來推動成長，其中包括 FDA核准的用於治療思覺失調症和雙相情感障礙 I 型的 2 個月緩釋注射劑（2022 年）。
  • 棕櫚酸帕利哌酮佔第二大的市場佔有率，這要歸功於 Invega Hafiera（2021 年），這是一種每年注射兩次的製劑，也是第一個核准用於治療成人思覺失調症的藥物。
  • 其他藥物也因可供選擇的種類繁多而助長了市場主導地位。

按分銷管道：

  • 由於大多數抗精神病藥物需要處方箋和後續觀察，醫院藥房佔了最大的市場佔有率（到 2026 年將達到 43.54%）。
  • 由於網上藥局為患者提供了便利，預計它們將成長最快。
  • 藥局和零售藥局在續開處方箋和供應口服藥物方面仍然發揮著至關重要的作用。

區域趨勢

  • 北美：受普及、研發和技術採用的推動，預計到 2025 年市場規模將達到 96.9 億美元，到 2026 年將達到 103.3 億美元。
  • 歐洲：2025年為39.1億美元，2026年為41.3億美元。政府的大力投入和不斷提高的意識正在推動市場成長。
  • 亞太地區：預計到 2025 年將達到 37.3 億美元，到 2026 年將達到 40.3 億美元。這是成長最快的地區，主要由中國和印度等新興經濟體推動。
  • 拉丁美洲：2025年為7.4億美元，2026年為7.7億美元。人們意識的提高和醫療保健支出的增加是推動這一成長的主要因素。
  • 非洲與中東：2025 年為 4.5 億美元，2026 年為 4.6 億美元。雖然市場佔有率有限，但由於醫療基礎設施的改善，市場佔有率正在成長。

市場趨勢和促進因素

1. 採用長效注射劑（LAI）：長效注射劑可提高病患的用藥遵從性，並降低復發風險。例如，帕利哌酮長效注射劑每年只需注射四次。

2. 研究與開發 (R&D) 措施：像 Karuna Therapeutics 這樣的公司正在開發創新藥物，例如 KarXT，用於治療與思覺失調症和阿茲海默症相關的精神病症狀。

3. 精神疾病盛行率上升：世界衛生組織預測，到 2030 年，精神疾病將對全球經濟造成 6 兆美元的損失，而且預計需求還會進一步增加。

抑制因子

體重增加、鎮靜、消化器官系統問題和遲發性運動障礙等副作用會導致患者用藥順從性下降。此外，諸如針對失智症患者的黑框警告等也會限制藥物的市場滲透率。

主要企業

  • 強生全球服務有限公司 - Invega Sustaina、 Risperdal Constellation
  • 大塚製藥株式會社 - Abilify Maintainer，Lexalti
  • 禮來公司－多種抗精神病藥物
  • Teva Pharmaceutical Industries、H. Lundbeck、Bristol-Myers Squibb、Dr. Reddy's Laboratories、Sumitomo Dai Nippon Pharma、Alkermes

產業趨勢

  • 2024 年 1 月：梯瓦製藥完成了每月一次的Olanzapine平長效注射劑的 3 期試驗。
  • 2023 年 4 月：FDA核准了Teva 和 MedinCel 生產的 UZEDY（RisperidoneLAI）。
  • 2022 年 1 月：FDA核准REXULTI 用於治療 13-17 歲患有思覺失調症的青少年。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 主要國家/地區精神疾病盛行率
  • 精神疾病的成本與負擔分析
  • 抗精神病藥物研發最新趨勢概述
  • 管道分析，主要企業
  • 分析：第一代抗精神病藥物與第三代抗精神病藥物
  • 重大產業發展、併購等。
  • 新產品發布
  • 新冠疫情的影響：抗精神病藥物市場

第5章：2021-2034年全球抗精神病藥物市場分析、洞察與預測

  • 市場分析、洞察與預測：按疾病分類。
    • 思覺失調症
    • 躁鬱症
    • 單相憂鬱症
    • 失智症
    • 其他
  • 市場分析、洞察與預測：按藥物分類
    • Risperidone
    • Quetiapine
    • Olanzapine
    • Aripiprazole
    • Brexpiprazole
    • 棕櫚酸帕利哌酮
    • 其他
  • 市場分析、洞察與預測：按治療類別分類
    • 第一代
    • 第二代
    • 第三代
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 藥局和零售藥房
    • 網路藥房
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美抗精神病藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲抗精神病藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區抗精神病藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲抗精神病藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲抗精神病藥物市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2026 年）
  • 公司簡介
    • Otsuka Pharmaceutical Co., Ltd.
    • Janssen Pharmaceuticals, Inc.（Johnson & Johnson）
    • Teva Pharmaceutical Industries Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • H. Lundbeck A/S
    • ALLERGAN（AbbVie, Inc.）
    • Eli Lilly and Company
    • Alkermes plc
    • Bristol-Myers Squibb Company
    • Sumitomo Dainippon Pharma Co., Ltd.
Product Code: FBI101390

Growth Factors of antipsychotic drugs Market

The global antipsychotic drugs market was valued at USD 18.51 billion in 2025 and is projected to grow to USD 19.71 billion in 2026, ultimately reaching USD 27.48 billion by 2034, exhibiting a CAGR of 5.24% during the forecast period. North America dominated the global market in 2025 with a share of 52.32%, driven by the high prevalence of psychiatric illnesses, strong presence of leading biopharmaceutical companies, and the adoption of technologically advanced antipsychotic medications.

Market Overview

Psychiatric illnesses, including schizophrenia, bipolar disorder, and depression, are the primary drivers of the antipsychotic drugs market. Psychosis, a key symptom of these illnesses, affects patients' perception of reality and information processing. The rising prevalence of schizophrenia and bipolar disorder has fueled the demand for effective antipsychotic medications globally. Moreover, the adoption of newer drug formulations, particularly long-acting injectables (LAIs), has significantly enhanced treatment adherence and outcomes.

COVID-19 also influenced the market positively by accelerating the transition toward telemedicine for psychiatric care, which increased medication adoption. Market growth is expected to stabilize between 2024 and 2032 due to improved healthcare systems and treatment accessibility.

Market Segmentation

By Disease:

  • Schizophrenia: The fastest-growing segment due to its global prevalence and the launch of multiple innovative products.
  • Bipolar Disorder: Second-largest segment, with drugs helping stabilize symptoms. Lifetime prevalence is around 1%, with a one-year prevalence of 0.5%.
  • Unipolar Depression: Third-largest segment, with medications like Rexulti providing symptomatic relief.
  • Dementia: Smaller segment due to the FDA black box warning limiting antipsychotic use in elderly patients.

By Therapeutic Class:

  • Second Generation Antipsychotics dominated with a 76.12% share in 2026, thanks to a superior safety profile and drugs like SEROQUEL XR, ZYPREXA, VRAYLAR, INVEGA HAFYERA, and Rexulti.
  • Third Generation is expected to exhibit the highest CAGR, supported by new product launches and technological advancements.
  • First Generation shows the lowest growth due to higher risk of neurological side effects.

By Drug:

  • Aripiprazole leads in growth due to third-generation adoption and significant product approvals, including the FDA-approved 2-month LAI for schizophrenia and bipolar I disorder (2022).
  • Paliperidone Palmitate holds the second-largest market share, with INVEGA HAFYERA being the first twice-yearly injectable approved for schizophrenia in adults (2021).
  • Other drugs contribute to market dominance due to the variety of available options.

By Distribution Channel:

  • Hospital pharmacies account for the largest market share (43.54% in 2026) as most antipsychotics require prescription and monitoring.
  • Online pharmacies are expected to grow the fastest due to patient convenience.
  • Drug stores & retail pharmacies remain significant for prescription refills and oral medications.

Regional Insights

  • North America: Market size USD 9.69 billion in 2025, projected USD 10.33 billion in 2026, dominating due to prevalence, R&D, and technological adoption.
  • Europe: USD 3.91 billion in 2025, USD 4.13 billion in 2026; strong government spending and awareness boost market growth.
  • Asia Pacific: USD 3.73 billion in 2025, USD 4.03 billion in 2026; fastest-growing region due to emerging countries like China and India.
  • Latin America: USD 0.74 billion in 2025, USD 0.77 billion in 2026; growth driven by increased awareness and healthcare expenditure.
  • Middle East & Africa: USD 0.45 billion in 2025, USD 0.46 billion in 2026; limited share but growing due to improved healthcare systems.

Market Trends and Growth Drivers

1. Adoption of Long-Acting Injectables (LAIs): LAIs improve adherence and reduce relapse risks. For example, Paliperidone LAIs require administration only four times a year.

2. R&D Initiatives: Companies like Karuna Therapeutics are developing innovative drugs like KarXT for schizophrenia and psychosis in Alzheimer's.

3. Rising Prevalence of Mental Disorders: WHO predicts mental disorders will cost the global economy USD 6 trillion by 2030, intensifying demand.

Restraining Factors

Adverse effects, including weight gain, sedation, digestive issues, and tardive dyskinesia, can lead to non-adherence. Black box warnings, such as for dementia patients, also limit market adoption.

Key Players

  • Janssen Global Services LLC - Invega Sustenna, Risperdal Consta
  • Otsuka Pharmaceutical Co., Ltd. - Abilify Maintena, Rexulti
  • Eli Lilly and Company - Various antipsychotics
  • Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Bristol-Myers Squibb, Dr. Reddy's Laboratories, Sumitomo Dainippon Pharma Co., Alkermes plc

Industry Developments

  • January 2024: Teva completes Phase 3 trial for once-monthly olanzapine LAI.
  • April 2023: FDA approves UZEDY (risperidone LAI) by Teva and MedinCell.
  • January 2022: FDA approves REXULTI for adolescents (13-17 years) with schizophrenia.

Conclusion

The global antipsychotic drugs market is poised for steady growth from 2025 to 2034, driven by rising mental health disorders, innovative LAIs, and active R&D pipelines. North America will continue to lead, while Asia Pacific emerges as the fastest-growing market, supported by awareness programs and increasing patient adoption of modern therapies.

Segmentation By Disease

  • Schizophrenia
  • Bipolar Disorder
  • Unipolar Depression
  • Dementia
  • Others

By Drug

  • Risperidone
  • Quetiapine
  • Olanzapine
  • Aripiprazole
  • Brexpiprazole
  • Paliperidone Palmitate
  • Others

By Therapeutic Class

  • First Generation
  • Second Generation
  • Third Generation

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Disease, By Drug, By Therapeutic Class, By Distribution Channel, By Country)
    • U.S. (By Disease)
    • Canada (By Disease)
  • Europe (By Disease, By Drug, By Therapeutic Class, By Distribution Channel, By Country/Sub-Region)
    • Germany (By Disease)
    • U.K. (By Disease)
    • France (By Disease)
    • Italy (By Disease)
    • Spain (By Disease)
    • Scandinavia (By Disease)
    • Rest of Europe (By Disease)
  • Asia Pacific (By Disease, By Drug, By Therapeutic Class, By Distribution Channel, By Country/Sub-Region)
    • China (By Disease)
    • Japan (By Disease)
    • India (By Disease)
    • Australia (By Disease)
    • Southeast Asia (By Disease)
    • Rest of Asia Pacific (By Disease)
  • Latin America (By Disease, By Drug, By Therapeutic Class, By Distribution Channel, By Country/Sub-Region)
    • Brazil (By Disease)
    • Mexico (By Disease)
    • Rest of Latin America (By Disease)
  • Middle East & Africa (By Disease, By Drug, By Therapeutic Class, By Distribution Channel, By Country/Sub-Region)
    • GCC (By Disease)
    • South Africa (By Disease)
    • Rest of Middle East & Africa (By Disease)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Psychiatric Disorders, By Key Countries/Regions
  • 4.2. Analysis of the Cost and Burden of Mental Health Disorders
  • 4.3. Overview of Current Advances in R&D for Antipsychotic Drugs
  • 4.4. Pipeline Analysis, Key Players
  • 4.5. Analysis: First Generation Antipsychotics vs. Third Generation Antipsychotics
  • 4.6. Key Industry Developments, Mergers, Acquisitions, Etc.
  • 4.7. New Product Launches
  • 4.8. Impact of COVID-19 on Antipsychotic Drugs Market

5. Global Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast- By Disease
    • 5.1.1. Schizophrenia
    • 5.1.2. Bipolar Disorder
    • 5.1.3. Unipolar Depression
    • 5.1.4. Dementia
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast- By Drug
    • 5.2.1. Risperidone
    • 5.2.2. Quetiapine
    • 5.2.3. Olanzapine
    • 5.2.4. Aripiprazole
    • 5.2.5. Brexpiprazole
    • 5.2.6. Paliperidone Palmitate
    • 5.2.7. Others
  • 5.3. Market Analysis, Insights and Forecast - By Therapeutic Class
    • 5.3.1. First Generation
    • 5.3.2. Second Generation
    • 5.3.3. Third Generation
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Drug Stores & Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast- By Disease
    • 6.1.1. Schizophrenia
    • 6.1.2. Bipolar Disorder
    • 6.1.3. Unipolar Depression
    • 6.1.4. Dementia
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast- By Drug
    • 6.2.1. Risperidone
    • 6.2.2. Quetiapine
    • 6.2.3. Olanzapine
    • 6.2.4. Aripiprazole
    • 6.2.5. Brexpiprazole
    • 6.2.6. Paliperidone Palmitate
    • 6.2.7. Others
  • 6.3. Market Analysis, Insights and Forecast - By Therapeutic Class
    • 6.3.1. First Generation
    • 6.3.2. Second Generation
    • 6.3.3. Third Generation
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Drug Stores & Retail Pharmacies
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
      • 6.5.1.1. By Disease
    • 6.5.2. Canada
      • 6.5.2.1. By Disease

7. Europe Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast- By Disease
    • 7.1.1. Schizophrenia
    • 7.1.2. Bipolar Disorder
    • 7.1.3. Unipolar Depression
    • 7.1.4. Dementia
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast- By Drug
    • 7.2.1. Risperidone
    • 7.2.2. Quetiapine
    • 7.2.3. Olanzapine
    • 7.2.4. Aripiprazole
    • 7.2.5. Brexpiprazole
    • 7.2.6. Paliperidone Palmitate
    • 7.2.7. Others
  • 7.3. Market Analysis, Insights and Forecast - By Therapeutic Class
    • 7.3.1. First Generation
    • 7.3.2. Second Generation
    • 7.3.3. Third Generation
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Drug Stores & Retail Pharmacies
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
      • 7.5.1.1. By Disease
    • 7.5.2. U.K.
      • 7.5.2.1. By Disease
    • 7.5.3. France
      • 7.5.3.1. By Disease
    • 7.5.4. Italy
      • 7.5.4.1. By Disease
    • 7.5.5. Spain
      • 7.5.5.1. By Disease
    • 7.5.6. Scandinavia
      • 7.5.6.1. By Disease
    • 7.5.7. Rest of Europe
      • 7.5.7.1. By Disease

8. Asia Pacific Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast- By Disease
    • 8.1.1. Schizophrenia
    • 8.1.2. Bipolar Disorder
    • 8.1.3. Unipolar Depression
    • 8.1.4. Dementia
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast- By Drug
    • 8.2.1. Risperidone
    • 8.2.2. Quetiapine
    • 8.2.3. Olanzapine
    • 8.2.4. Aripiprazole
    • 8.2.5. Brexpiprazole
    • 8.2.6. Paliperidone Palmitate
    • 8.2.7. Others
  • 8.3. Market Analysis, Insights and Forecast - By Therapeutic Class
    • 8.3.1. First Generation
    • 8.3.2. Second Generation
    • 8.3.3. Third Generation
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Drug Stores & Retail Pharmacies
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
      • 8.5.1.1. By Disease
    • 8.5.2. India
      • 8.5.2.1. By Disease
    • 8.5.3. Japan
      • 8.5.3.1. By Disease
    • 8.5.4. Australia
      • 8.5.4.1. By Disease
    • 8.5.5. Southeast Asia
      • 8.5.5.1. By Disease
    • 8.5.6. Rest of Asia Pacific
      • 8.5.6.1. By Disease

9. Latin America Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast- By Disease
    • 9.1.1. Schizophrenia
    • 9.1.2. Bipolar Disorder
    • 9.1.3. Unipolar Depression
    • 9.1.4. Dementia
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast- By Drug
    • 9.2.1. Risperidone
    • 9.2.2. Quetiapine
    • 9.2.3. Olanzapine
    • 9.2.4. Aripiprazole
    • 9.2.5. Brexpiprazole
    • 9.2.6. Paliperidone Palmitate
    • 9.2.7. Others
  • 9.3. Market Analysis, Insights and Forecast - By Therapeutic Class
    • 9.3.1. First Generation
    • 9.3.2. Second Generation
    • 9.3.3. Third Generation
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Drug Stores & Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
      • 9.5.1.1. By Disease
    • 9.5.2. Mexico
      • 9.5.2.1. By Disease
    • 9.5.3. Rest of Latin America
      • 9.5.3.1. By Disease

10. Middle East & Africa Antipsychotic Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast- By Disease
    • 10.1.1. Schizophrenia
    • 10.1.2. Bipolar Disorder
    • 10.1.3. Unipolar Depression
    • 10.1.4. Dementia
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast- By Drug
    • 10.2.1. Risperidone
    • 10.2.2. Quetiapine
    • 10.2.3. Olanzapine
    • 10.2.4. Aripiprazole
    • 10.2.5. Brexpiprazole
    • 10.2.6. Paliperidone Palmitate
    • 10.2.7. Others
  • 10.3. Market Analysis, Insights and Forecast - By Therapeutic Class
    • 10.3.1. First Generation
    • 10.3.2. Second Generation
    • 10.3.3. Third Generation
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Drug Stores & Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
      • 10.5.1.1. By Disease
    • 10.5.2. South Africa
      • 10.5.2.1. By Disease
    • 10.5.3. Rest of Middle East & Africa
      • 10.5.3.1. By Disease

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2026)
  • 11.2. Company Profiles
    • 11.2.1. Otsuka Pharmaceutical Co., Ltd.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Teva Pharmaceutical Industries Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Dr. Reddy's Laboratories Ltd.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. H. Lundbeck A/S
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. ALLERGAN (AbbVie, Inc.)
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Eli Lilly and Company
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Alkermes plc
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Bristol-Myers Squibb Company
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & Services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Sumitomo Dainippon Pharma Co., Ltd.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & Services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 01: Global Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 02: Global Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 03: Global Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Therapeutic Class, 2021-2034
  • Table 04: Global Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 05: Global Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 06: North America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 07: North America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 08: North America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Therapeutic Class, 2021-2034
  • Table 09: North America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 10: North America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: U.S. Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 12: Canada Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 13: Europe Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 14: Europe Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 15: Europe Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Therapeutic Class, 2021-2034
  • Table 16: Europe Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 17: Europe Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 18: Germany Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 19: U.K. Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 20: France Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 21: Italy Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 22: Spain Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 23: Scandinavia Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 24: Rest of Europe Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 25: Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 26: Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 27: Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Therapeutic Class, 2021-2034
  • Table 28: Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 29: Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 30: Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 31: China Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 32: India Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 33: Japan Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 34: Australia Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 35: South East Asia Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 36: Rest of Asia Pacific Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 37: Latin America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 38: Latin America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 39: Latin America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Therapeutic Class, 2021-2034
  • Table 40: Latin America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 41: Latin America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 42: Brazil Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 43: Mexico Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 44: Rest of Latin America Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 45: Middle East & Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 46: Middle East & Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 47: Middle East & Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Therapeutic Class, 2021-2034
  • Table 48: Middle East & Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 49: Middle East & Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 50: South Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 51: GCC Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034
  • Table 52: Rest of Middle East & Africa Antipsychotic Drugs Market Revenue (USD billion) Forecast, By Disease, 2021-2034

List of Figures

  • Figure 01: Global Antipsychotic Drugs Market Value Share (%), By Disease, 2026 & 2034
  • Figure 02: Global Antipsychotic Drugs Market Value Share (%), By Drug, 2026 & 2034
  • Figure 03: Global Antipsychotic Drugs Market Value Share (%), By Therapeutic Class, 2026 & 2034
  • Figure 04: Global Antipsychotic Drugs Market Value Share (%), By Distribution Channel, 2026 & 2034
  • Figure 05: Global Antipsychotic Drugs Market Value Share (%), By Region, 2026 & 2034
  • Figure 06: North America Antipsychotic Drugs Market Value (USD billion), By Disease, 2026 & 2034
  • Figure 07: North America Antipsychotic Drugs Market Value Share (%), By Disease, 2026
  • Figure 08: North America Antipsychotic Drugs Market Value (USD billion), By Drug, 2026 & 2034
  • Figure 09: North America Antipsychotic Drugs Market Value Share (%), By Drug, 2026
  • Figure 10: North America Antipsychotic Drugs Market Value (USD billion), By Therapeutic Class, 2026 & 2034
  • Figure 11: North America Antipsychotic Drugs Market Value Share (%), By Therapeutic Class, 2026
  • Figure 12: North America Antipsychotic Drugs Market Value (USD billion), By Distribution Channel, 2026 & 2034
  • Figure 13: North America Antipsychotic Drugs Market Value Share (%), By Distribution Channel, 2026
  • Figure 14: North America Antipsychotic Drugs Market Value (USD billion), By Country, 2026 & 2034
  • Figure 15: North America Antipsychotic Drugs Market Value Share (%), By Country, 2026
  • Figure 16: Europe Antipsychotic Drugs Market Value (USD billion), By Disease, 2026 & 2034
  • Figure 17: Europe Antipsychotic Drugs Market Value Share (%), By Disease, 2026
  • Figure 18: Europe Antipsychotic Drugs Market Value (USD billion), By Drug, 2026 & 2034
  • Figure 19: Europe Antipsychotic Drugs Market Value Share (%), By Drug, 2026
  • Figure 20: Europe Antipsychotic Drugs Market Value (USD billion), By Therapeutic Class, 2026 & 2034
  • Figure 21: Europe Antipsychotic Drugs Market Value Share (%), By Therapeutic Class, 2026
  • Figure 22: Europe Antipsychotic Drugs Market Value (USD billion), By Distribution Channel, 2026 & 2034
  • Figure 23: Europe Antipsychotic Drugs Market Value Share (%), By Distribution Channel, 2026 & 2034
  • Figure 24: Europe Antipsychotic Drugs Market Value (USD billion), By Country/Sub-region, 2026 & 2034
  • Figure 25: Europe Antipsychotic Drugs Market Value Share (%), By Country/Sub-region, 2026
  • Figure 26: Asia Pacific Antipsychotic Drugs Market Value (USD billion), By Disease, 2026 & 2034
  • Figure 27: Asia Pacific Antipsychotic Drugs Market Value Share (%), By Disease, 2026
  • Figure 28: Asia Pacific Antipsychotic Drugs Market Value (USD billion), By Drug, 2026 & 2034
  • Figure 29: Asia Pacific Antipsychotic Drugs Market Value Share (%), By Drug, 2026
  • Figure 30: Asia Pacific Antipsychotic Drugs Market Value (USD billion), By Therapeutic Class, 2026 & 2034
  • Figure 31: Asia Pacific Antipsychotic Drugs Market Value Share (%), By Therapeutic Class, 2026
  • Figure 32: Asia Pacific Antipsychotic Drugs Market Value (USD billion), By Distribution Channel, 2026 & 2034
  • Figure 33: Asia Pacific Antipsychotic Drugs Market Value Share (%), By Distribution Channel, 2026
  • Figure 34: Asia Pacific Antipsychotic Drugs Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 35: Asia Pacific Antipsychotic Drugs Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 36: Latin America Antipsychotic Drugs Market Value (USD billion), By Disease, 2026 & 2034
  • Figure 37: Latin America Antipsychotic Drugs Market Value Share (%), By Disease, 2026
  • Figure 38: Latin America Antipsychotic Drugs Market Value (USD billion), By Drug, 2026 & 2034
  • Figure 39: Latin America Antipsychotic Drugs Market Value Share (%), By Drug, 2026
  • Figure 40: Latin America Antipsychotic Drugs Market Value (USD billion), By Therapeutic Class, 2026 & 2034
  • Figure 41: Latin America Antipsychotic Drugs Market Value Share (%), By Therapeutic Class, 2026
  • Figure 42: Latin America Antipsychotic Drugs Market Value (USD billion), By Distribution Channel, 2026 & 2034
  • Figure 43: Latin America Antipsychotic Drugs Market Value Share (%), By Distribution Channel, 2026
  • Figure 44: Latin America Antipsychotic Drugs Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 45: Latin America Antipsychotic Drugs Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 46: Middle East & Africa Antipsychotic Drugs Market Value (USD billion), By Disease, 2026 & 2034
  • Figure 47: Middle East & Africa Antipsychotic Drugs Market Value Share (%), By Disease, 2026
  • Figure 48: Middle East & Africa Antipsychotic Drugs Market Value (USD billion), By Drug, 2026 & 2034
  • Figure 49: Middle East & Africa Antipsychotic Drugs Market Value Share (%),
  • Figure 50: Middle East & Africa Antipsychotic Drugs Market Value (USD billion), By Therapeutic Class, 2026 & 2034
  • Figure 51: Middle East & Africa Antipsychotic Drugs Market Value Share (%), By Therapeutic Class, 2026
  • Figure 52: Middle East & Africa Antipsychotic Drugs Market Value (USD billion), By Distribution Channel 2026 & 2034
  • Figure 53: Middle East & Africa Antipsychotic Drugs Market Value Share (%), By Distribution Channel, 2026
  • Figure 54: Middle East & Africa Antipsychotic Drugs Market Value (USD billion), By Country/ Sub-region, 2026 & 2034
  • Figure 55: Middle East & Africa Antipsychotic Drugs Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 56: Global Antipsychotic Drugs Market Share Analysis, By Company, 2026